优化维洛贝利马布用于治疗COVID-19的使用
1Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America.
Expert opinion on biological therapy
|July 8, 2023
概括
针对5a配方成分的抗体Vilobelimab获得了针对严重COVID-19的紧急使用授权. 在通风患者的治疗减少了60日死亡的风险.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- SARS-CoV-2 感染会通过系统性炎症引起严重的COVID-19.
- 补充成分5a (C5a) 涉及到COVID-19的致病性.
- 维洛贝利马布是一种单克隆抗体,向C5a.
研究的目的:
- 评估维洛贝利马布在重症COVID-19患者的疗效和安全性.
- 探索C5a抑制在控制COVID-19相关炎症中的作用.
主要方法:
- 进行了一项随机的,多中心的,适应性的II/III期临床试验.
- 包括需要侵入性机械通风的严重COVID-19患者.
- 治疗包括维洛贝利马布加常规护理与安慰剂加常规护理.
主要成果:
- 在机械呼吸患者中,维洛贝利马布治疗显著降低了28日和60日死亡的风险.
- 该研究表明,维洛贝利马布的安全性概况有利.
结论:
- 维洛贝利马布 (Vilobelimab) 是一种有前途的治疗方案,用于治疗严重的COVID-19.
- 向C5a可能会减轻炎症反应,并改善COVID-19危急患者的治疗结果.
关键词:
在C5a中,它是C5a.在 COVID-19 疫情中,补充 补充 补充 补充戈希比克 (Gohibic) 是一个古巴人.这就是SARS-CoV-2病毒.补充补充补充补充补充补充补充.这里是可靠的房子.更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.4K
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
9.5K
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
250
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
250
Subviral Agents
45
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
45
Pneumonia IV: Management
367
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
367
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
